Articles On Paradigm Biopharmaceuticals (ASX:PAR)

The company is focused on repurposing the injectable drug pentosan polysulphate sodium to treat inflammation in MPS VI patients.

Growing ASX-listed biotech company Paradigm Biopharmaceuticals Ltd (ASX: PAR) has performed strongly over the last year, with Paradigm shares skyrocketing more than 250% higher to $4.20 as at the time of writing. This means it has outperf...

The Opthea Ltd (ASX: OPT) share price has already surged over 20% higher in January to $3.60 as at the time of writing. Although the 52-week high of $4.15 the biotechnology company hit back in September still seems like a little way off ye...

With the market in fine form so far this year, it will come as no surprise to learn that a number of shares have just hit 52-week highs or better. Three shares that have just reached this milestone are listed below. Here’s why they are sca...

I’m a big fan of investing in the mid cap side of the market. This is because it generally offers greater potential returns that the large cap space, but comes with less risk than the small cap side of the market. Three mid cap ASX shares...

I’m sure that many readers have aspirations to become a millionaire one day. And while a lucky few may achieve this through buying a lottery ticket on the Jumbo Interactive Ltd (ASX: JIN) operated Oz Lotteries website, the odds are certain...

I think that one of the best ways to make market-beating returns is to have a little exposure to the small cap side of the market. After all, it wasn’t that long ago that Altium Limited (ASX: ALU) and Appen Ltd (ASX: APX) were classed as s...

Due to a number of positive trends such as increased chronic disease burden and ageing populations, I believe the healthcare sector is one of the best places to invest your money with a long term view. With that in mind, here are three ver...

Over the last 12 months the Opthea Ltd (ASX: OPT) share price has been one of the best performers on the All Ordinaries index. During this time the shares of the developer of novel biologic therapies for the treatment of eye diseases have...

It was a great year for ASX healthcare shares in 2019, with the S&P/ASX Healthcare Index increasing by 41%. These 3 ASX healthcare shares experienced even greater gains in 2019, but can they continue to outperform in 2020?  Avita Med...

If your portfolio doesn’t have exposure to the small side of the market, I think it would be well worth considering adding one or two small cap shares to it if your risk profile allows. After all, you only need to look at Altium Limited (A...

There are more than 150 healthcare shares listed on the ASX, varying from pharmaceutical manufacturers, to medical software developers to facility operators. So where should you start if you want to add ASX healthcare shares to your portfo...

The S&P/ASX 200 index is ending the year with a day in the red. In afternoon trade the benchmark index is down a sizeable 1.7% to 6,688.7 points. Four shares that have not let that hold them back today are listed below. Here’s why they...

A new year is upon us, so what better time to look at potential new additions to your portfolio. If you’re interested in gaining a little exposure to the small side of the market, then the three ASX shares listed below could be the ones to...

Due to populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to rise. I believe this trend will continue for several decades, which could make the healthcare sector a gre...

On Christmas Day I picked out 10 top ASX shares that I think could be great options for investors in 2020. But they weren’t the only shares that I would be buying right now. Here are 10 more top ASX shares to own in 2020: Nearmap Ltd (ASX:...

In late trade S&P/ASX 200 index is having a subdued end to the day ahead of the Christmas break. At the time of writing the benchmark index is flat at 6,786.7 points. Four shares that are out of form on Tuesday are listed below. Here’s...

I think the Australian share market is home to a large number of small cap shares that have the potential to grow materially larger in the future. While history shows that not all small caps deliver on their potential, I think many of thes...

In afternoon trade the S&P/ASX 200 index has come under pressure and is trading notably lower. At the time of writing the benchmark index is down 0.75% to 6,701.9 points. Four shares that have fallen more than most today are listed bel...

With progress to secure regulatory approvals underway for its flagship Zilosul treatment Paradigm Biopharmaceuticals (ASX: PAR) is also gearing up for phase 2/3 clinical trial in the first quarter of next year. Paradigm is preparing for a j...

In morning trade the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is sinking lower despite the release of its end of year update. At the time of writing the biopharmaceutical company’s shares are down 4% to $3.00. What was in Par...

Paradigm will be meeting with the US FDA in Feb 2020 for a pre-IND meeting among other things.

The S&P/ASX 200 index has returned to form and is pushing higher this afternoon. At the time of writing the benchmark index is up 0.4% to 6,732.4 points. Four shares that have failed to follow the market higher today are listed below....

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year’s day 2019 to $3.49 today and even hit as high as $4.12 last November. What does Paradigm do? With its shares up 250% in less than a year you’d think Paradi...

The S&P/ASX 200 index has followed the lead of U.S. markets and is dropping lower today. At the time of writing the benchmark index is down 0.15% to 6,719.8 points. Four shares that have fallen more than most today are listed below. He...

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

CSL Limited (ASX: CSL) will go down as one of the greatest growth stories of all time. The company has been unshakeable in its ability to deliver consistent earnings growth and shareholder value for more than 2 decades. But for many inves...

With populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to increase. I expect this trend to continue for several decades, which I feel makes the healthcare sector a gr...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters, soaring more than 20% in the past 5 days, before dipping back slightly in yesterday’s trade to close down 1.87%. Paradigm is a late stage ASX-listed biotechn...

I think the mid cap space is a great place to look for buy and hold investment ideas. This is because I believe there are a good number of shares that have the potential to grow strongly over the next decade, potentially generating outsize...

Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.

The S&P/ASX 200 index has recovered from a spot of late morning weakness and is pushing higher in afternoon trade. At the time of writing the benchmark index is up a solid 0.4% to 6,795.4 points. Four shares that are climbing more than...

The Alcidion Group Ltd (ASX: ALC) share price has been a positive performer on Tuesday. In morning trade the healthcare technology company’s shares were up 8% to 20.5 cents at one stage. Why did the Alcidion share price surge higher? Inves...

Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.

Australia’s health care industry is one of the fastest growing industries in the country that is making substantial progress driven by new technological advancements. The country’s government is injecting billions of dollars into modernisin...

The Novita Healthcare Ltd (ASX: NHL) share price is down 7% to 9.1 cents today, but up around 8x from 1.1 cents on October 23 after the biotech handed investors some big news. On October 24 hardly known Novita told investors its TALi Detec...

In afternoon trade the S&P/ASX 200 index has given back its morning gains and dropped lower. At the time of writing the benchmark index is trading 0.2% lower at 6,714.3 points. Four shares that have not let that hold them back are list...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was on form again on Thursday. The biopharmaceutical company’s shares pushed 4% higher to $2.93 on the day of its annual general meeting. This latest gain means the Paradigm share...

The biotech gained up to 5% by lunch on confirming FY20 milestones, including an early-2020 filing with the US FDA for an OA drug.

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The Next Science Ltd (ASX: NXS) share price has slipped 5% to $2.52 today but investors shouldn’t be disheartened as the stock is still up 150% from its April 2019 $1 per share initial public offer price.  For the quarter ending September...

The Novita Healthcare Ltd (ASX: NHL) share price is now up around 4.5x or 350% since last week. That’s not a typo either as the early learning childhood technology business reported that its TALi Detect platform could be delivered via the...

The S&P/ASX 200 index is on course to start the week on a positive note. In afternoon trade the benchmark index is up 0.15% to 6,749.7 points. Four shares climbing more than most today are listed below. Here’s why they are storming hig...

It has been a very positive end to the week for the S&P/ASX 200 index. In afternoon trade the benchmark index is up a solid 0.65% to 6,737 points. Four shares that have climbed more than most today are listed below. Here’s why they are...

The IRB has followed the FDA in approving the submission to treat 10 ex NFL players with Paradigm’s trial drug Zilosul.

Paradigm Biopharmaceuticals (ASX: PAR) has been given the go-ahead by US regulators to treat 10 former NFL players with its pentosan polysulfate sodium (iPPS) drug, otherwise known as Zilosul. Following the successful US Food and Drug Admin...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters in 2019 as wild investor excitement mounts over its Zilosul drug’s commercial potential. The biotech now has a market value around $516 million despite posting...

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the market. On September 23 the little-known surgical material business joined the S&P/ ASX200 (ASX: XJO) in...

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions.  CelGro® is r...

Health care, being the dynamic sector, keep investors on their toes before injecting their funds. Vigilance to information is an important criterion that allows investors and market enthusiasts to capitalise money in the stocks. Variables p...